Syndax Pharmaceuticals, Inc. (SNDX): Price and Financial Metrics


Syndax Pharmaceuticals, Inc. (SNDX): $19.07

-0.17 (-0.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SNDX POWR Grades


  • SNDX scores best on the Value dimension, with a Value rank ahead of 87.99% of US stocks.
  • SNDX's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • SNDX's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

SNDX Stock Summary

  • Of note is the ratio of Syndax Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 9.24% of US stocks have a lower such ratio.
  • SNDX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 11.62% of US stocks.
  • Revenue growth over the past 12 months for Syndax Pharmaceuticals Inc comes in at 9,109.56%, a number that bests 99.76% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Syndax Pharmaceuticals Inc, a group of peers worth examining would be RPTX, KDNY, TGTX, VIR, and LYRA.
  • Visit SNDX's SEC page to see the company's official filings. To visit the company's web site, go to www.syndax.com.

SNDX Valuation Summary

  • SNDX's price/earnings ratio is -8.9; this is 124.38% lower than that of the median Healthcare stock.
  • Over the past 67 months, SNDX's price/sales ratio has gone up 228.3.
  • Over the past 67 months, SNDX's price/sales ratio has gone up 228.3.

Below are key valuation metrics over time for SNDX.

Stock Date P/S P/B P/E EV/EBIT
SNDX 2021-08-31 561.0 4.0 -8.9 -8.6
SNDX 2021-08-30 553.3 3.9 -8.8 -8.5
SNDX 2021-08-27 541.8 3.8 -8.6 -8.3
SNDX 2021-08-26 529.6 3.7 -8.4 -8.1
SNDX 2021-08-25 544.0 3.8 -8.6 -8.4
SNDX 2021-08-24 539.2 3.8 -8.6 -8.3

SNDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SNDX has a Quality Grade of D, ranking ahead of 17.57% of graded US stocks.
  • SNDX's asset turnover comes in at 0.006 -- ranking 405th of 682 Pharmaceutical Products stocks.
  • SYRS, LFVN, and ICPT are the stocks whose asset turnover ratios are most correlated with SNDX.

The table below shows SNDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.006 1 -0.517
2021-03-31 0.006 1 -0.517
2020-12-31 0.008 1 -0.570
2020-09-30 0.011 1 -0.727
2020-06-30 0.014 1 -0.906
2020-03-31 0.018 1 -1.474

SNDX Price Target

For more insight on analysts targets of SNDX, see our SNDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.67 Average Broker Recommendation 1.36 (Strong Buy)

SNDX Stock Price Chart Interactive Chart >

Price chart for SNDX

SNDX Price/Volume Stats

Current price $19.07 52-week high $22.71
Prev. close $19.24 52-week low $13.27
Day low $18.61 Volume 350,200
Day high $19.47 Avg. volume 556,901
50-day MA $16.34 Dividend yield N/A
200-day MA $17.45 Market Cap 1.07B

Syndax Pharmaceuticals, Inc. (SNDX) Company Bio


Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company was founded in 2005 and is based in Waltham, Massachusetts.


SNDX Latest News Stream


Event/Time News Detail
Loading, please wait...

SNDX Latest Social Stream


Loading social stream, please wait...

View Full SNDX Social Stream

Latest SNDX News From Around the Web

Below are the latest news stories about Syndax Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNDX as an investment opportunity.

The Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars game

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.

Yahoo | February 10, 2022

Soligenix to Present at the 2022 BIO CEO & Investor Conference

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Conference taking place February 14-17, 2022. The presentation will be available to registered conference attendees for on-demand vie

Yahoo | February 8, 2022

Syndax Pharmaceuticals names COO Michael Metzger as CEO

Syndax Pharmaceuticals (SNDX) said Michael Metzger, president and COO, will transition to the role of CEO, effective Feb

Seeking Alpha | February 3, 2022

Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, President and Chief Operating Officer, will transition to the role of Chief Executive Officer, effective today. Briggs W. Morrison, M.D., Chief Executive Officer, will transition to the role of President, Head of Research and Development (R&D). Mr. Metzger and Dr. Morrison will rem

Yahoo | February 3, 2022

Syndax Pharmaceuticals (SNDX) Investor Presentation - Slideshow

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 28, 2022

Read More 'SNDX' Stories Here

SNDX Price Returns

1-mo 14.88%
3-mo 8.23%
6-mo -13.91%
1-year 8.41%
3-year 108.42%
5-year 37.29%
YTD -12.88%
2021 -1.57%
2020 153.30%
2019 97.30%
2018 -49.20%
2017 22.18%

Continue Researching SNDX

Here are a few links from around the web to help you further your research on Syndax Pharmaceuticals Inc's stock as an investment opportunity:

Syndax Pharmaceuticals Inc (SNDX) Stock Price | Nasdaq
Syndax Pharmaceuticals Inc (SNDX) Stock Quote, History and News - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4586 seconds.